Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 1.00 |
| ▸ | APP | P05067 | 9/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | BACE2 | Q9Y5Z0 | 7/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9948515 | 0.88 | BACE1 (1.00) | BACE1APPBACE2KCNH2 | |
| SCHEMBL9948471 | 0.84 | BACE1 (0.72) | BACE1APPCYP2D6BACE2 | |
| SCHEMBL9948086 | 0.80 | BACE1 (1.00) | BACE1APPBACE2 | |
| SCHEMBL30069522 | 0.80 | BACE1 (0.66) | BACE1APPCYP2D6BACE2KCNH2 | |
| SCHEMBL10271120 | 0.79 | BACE1 (0.81) | BACE1APPBACE2 | |
| SCHEMBL1994805 | 0.79 | BACE1 (0.65) | BACE1APPCYP2D6BACE2KCNH2 | |
| SCHEMBL10271130 | 0.78 | BACE1 (0.81) | BACE1APPBACE2KCNH2 | |
| SCHEMBL9948287 | 0.78 | BACE1 (1.00) | BACE1APP | |
| SCHEMBL14053609 | 0.76 | BACE1 (0.62) | BACE1APPCYP2D6BACE2KCNH2 | |
| SCHEMBL14053610 | 0.76 | BACE1 (0.62) | BACE1APPCYP2D6BACE2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3176172-A1 | SPIROIMIDAZOLE COMPOUNDS AND THEIR USE AS BACE INHIBITORS | Astrazeneca AB (SE) | 2017-06-07 | — | — | EP | claimed |
| US-20160184303-A1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | ASTRAZENECA AB (SE) | 2016-06-30 | — | — | US | claimed |
| US-9248129-B2 | Compounds and their use as BACE inhibitors | ASTRAZENECA AB (SE) | 2016-02-02 | — | — | US | claimed |
| US-20150133471-A1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | ASTRAZENECA AB (SE) | 2015-05-14 | — | — | US | claimed |
| US-8865911-B2 | Compounds and their use as BACE inhibitors | ASTRAZENECA AB (SE) | 2014-10-21 | — | — | US | claimed |
| EP-2655378-A1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | AstraZeneca AB (SE) | 2013-10-30 | — | — | EP | claimed |
| US-20130210837-A1 | Compounds and Their Use as BACE Inhibitors | ASTRAZENECA INTELLECTUAL PROPERTY | 2013-08-15 | — | — | US | claimed |
| US-20120165347-A1 | Compounds and their use as BACE Inhibitors | ASTRAZENECA AB (SE) | 2012-06-28 | — | — | US | claimed |
| WO-2012087237-A1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | ASTRAZENECA AB (SE) | 2012-06-28 | — | — | WO | claimed |
| EP-3176172-B1 | SPIROIMIDAZOLE COMPOUNDS AND THEIR USE AS BACE INHIBITORS | ASTRAZENECA AB (SE) | 2020-01-29 | — | — | EP | disclosed |
| EP-3176172-B1 | SPIROIMIDAZOLE COMPOUNDS AND THEIR USE AS BACE INHIBITORS | ASTRAZENECA AB (SE) | 2020-01-29 | — | — | EP | disclosed |
| US-10231967-B2 | Compounds and their use as BACE inhibitors | ASTRAZENECA AB (SE) | 2019-03-19 | — | — | US | disclosed |
| US-10231967-B2 | Compounds and their use as BACE inhibitors | ASTRAZENECA AB (SE) | 2019-03-19 | — | — | US | disclosed |
| US-20180221367-A1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | ASTRAZENECA AB (SE) | 2018-08-09 | — | — | US | disclosed |
| US-8415483-B2 | Compounds and their use as BACE inhibitors | ASTRAZENECA AB (SE) | 2013-04-09 | — | — | US | disclosed |
| US-8415483-B2 | Compounds and their use as BACE inhibitors | ASTRAZENECA AB (SE) | 2013-04-09 | — | — | US | disclosed |
| US-20120165347-A1 | Compounds and their use as BACE Inhibitors | ASTRAZENECA AB (SE) | 2012-06-28 | — | — | US | disclosed |
| US-20120165347-A1 | Compounds and their use as BACE Inhibitors | ASTRAZENECA AB (SE) | 2012-06-28 | — | — | US | disclosed |
| WO-2012087237-A1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | ASTRAZENECA AB (SE) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012087237-A1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | ASTRAZENECA AB (SE) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133471-A1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | BACE1, BACE2, APP | BACE1 1/4885APP 3/4885CYP2D6 3824/4885 |
| US-20120165347-A1 | Compounds and their use as BACE Inhibitors | BACE1, BACE2, APP | BACE1 1/4885APP 3/4885CYP2D6 3824/4885 |
| US-20130210837-A1 | Compounds and Their Use as BACE Inhibitors | BACE1, BACE2, APP | BACE1 1/4885APP 3/4885CYP2D6 3824/4885 |
| US-10231967-B2 | Compounds and their use as BACE inhibitors | BACE1, BACE2, APP | BACE1 1/4885APP 3/4885CYP2D6 3824/4885 |
| US-20180221367-A1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | BACE1, BACE2, APP | BACE1 1/4885APP 3/4885CYP2D6 3824/4885 |
| US-20160184303-A1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | BACE1, BACE2, APP | BACE1 1/4885APP 3/4885CYP2D6 3824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.